arrow_back Back to App

Increased Funding for Fungal Disease Research and Antimicrobial Resistance Fight.

This law allocates significant funds to accelerate research into serious endemic fungal diseases, such as Valley Fever, and supports the development of new drugs and vaccines. It establishes a dedicated working group to coordinate federal efforts and incentivizes pharmaceutical companies to create new therapies. Crucially, it boosts the national program combating drug resistance, earmarking funds specifically for antifungal product development, improving public health security.
Key points
Authorizes $20 million annually (2024-2028) for NIH research into endemic fungal diseases, aiming for better treatments and diagnostics.
Establishes a new federal working group to coordinate research efforts and identify gaps in the development of therapies and vaccines for fungal diseases.
Adds Coccidioidomycosis (Valley Fever) to the Priority Review Voucher program, offering faster FDA review to incentivize drug companies.
Allocates at least 20% of $500 million in new funding to support the development of antifungal products to combat drug resistance.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_3464
Sponsor: Sen. Kelly, Mark [D-AZ]
Process start date: 2023-12-12
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

FORWARD Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_3464.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-12-12.

What are the main provisions?

Key points include:

  • Authorizes $20 million annually (2024-2028) for NIH research into endemic fungal diseases, aiming for better treatments and diagnostics.
  • Establishes a new federal working group to coordinate research efforts and identify gaps in the development of therapies and vaccines for fungal diseases.
  • Adds Coccidioidomycosis (Valley Fever) to the Priority Review Voucher program, offering faster FDA review to incentivize drug companies.
  • Allocates at least 20% of $500 million in new funding to support the development of antifungal products to combat drug resistance.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Kelly, Mark [D-AZ].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health Public Investments